Global Live Attenuated Herpes Zoster Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Live Attenuated Herpes Zoster Vaccine Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 40-50 Years Old
- 1.3.3 50-60 Years Old
- 1.3.4 60-70 Years Old
- 1.3.5 >70 Years Old
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global Live Attenuated Herpes Zoster Vaccine Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 Hospital
- 1.4.3 Clinic
- 1.4.4 Epidemic Prevention Center
- 1.4.5 Others
- 1.5 Global Live Attenuated Herpes Zoster Vaccine Market Size & Forecast
- 1.5.1 Global Live Attenuated Herpes Zoster Vaccine Consumption Value (2021 & 2025 & 2032)
- 1.5.2 Global Live Attenuated Herpes Zoster Vaccine Sales Quantity (2021-2032)
- 1.5.3 Global Live Attenuated Herpes Zoster Vaccine Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Merck & Co.
- 2.1.1 Merck & Co. Details
- 2.1.2 Merck & Co. Major Business
- 2.1.3 Merck & Co. Live Attenuated Herpes Zoster Vaccine Product and Services
- 2.1.4 Merck & Co. Live Attenuated Herpes Zoster Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Merck & Co. Recent Developments/Updates
- 2.2 SK Bioscience
- 2.2.1 SK Bioscience Details
- 2.2.2 SK Bioscience Major Business
- 2.2.3 SK Bioscience Live Attenuated Herpes Zoster Vaccine Product and Services
- 2.2.4 SK Bioscience Live Attenuated Herpes Zoster Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 SK Bioscience Recent Developments/Updates
- 2.3 GlaxoSmithKline (GSK)
- 2.3.1 GlaxoSmithKline (GSK) Details
- 2.3.2 GlaxoSmithKline (GSK) Major Business
- 2.3.3 GlaxoSmithKline (GSK) Live Attenuated Herpes Zoster Vaccine Product and Services
- 2.3.4 GlaxoSmithKline (GSK) Live Attenuated Herpes Zoster Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 GlaxoSmithKline (GSK) Recent Developments/Updates
- 2.4 Beike Bio
- 2.4.1 Beike Bio Details
- 2.4.2 Beike Bio Major Business
- 2.4.3 Beike Bio Live Attenuated Herpes Zoster Vaccine Product and Services
- 2.4.4 Beike Bio Live Attenuated Herpes Zoster Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Beike Bio Recent Developments/Updates
3 Competitive Environment: Live Attenuated Herpes Zoster Vaccine by Manufacturer
- 3.1 Global Live Attenuated Herpes Zoster Vaccine Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Live Attenuated Herpes Zoster Vaccine Revenue by Manufacturer (2021-2026)
- 3.3 Global Live Attenuated Herpes Zoster Vaccine Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Live Attenuated Herpes Zoster Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Live Attenuated Herpes Zoster Vaccine Manufacturer Market Share in 2025
- 3.4.3 Top 6 Live Attenuated Herpes Zoster Vaccine Manufacturer Market Share in 2025
- 3.5 Live Attenuated Herpes Zoster Vaccine Market: Overall Company Footprint Analysis
- 3.5.1 Live Attenuated Herpes Zoster Vaccine Market: Region Footprint
- 3.5.2 Live Attenuated Herpes Zoster Vaccine Market: Company Product Type Footprint
- 3.5.3 Live Attenuated Herpes Zoster Vaccine Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Live Attenuated Herpes Zoster Vaccine Market Size by Region
- 4.1.1 Global Live Attenuated Herpes Zoster Vaccine Sales Quantity by Region (2021-2032)
- 4.1.2 Global Live Attenuated Herpes Zoster Vaccine Consumption Value by Region (2021-2032)
- 4.1.3 Global Live Attenuated Herpes Zoster Vaccine Average Price by Region (2021-2032)
- 4.2 North America Live Attenuated Herpes Zoster Vaccine Consumption Value (2021-2032)
- 4.3 Europe Live Attenuated Herpes Zoster Vaccine Consumption Value (2021-2032)
- 4.4 Asia-Pacific Live Attenuated Herpes Zoster Vaccine Consumption Value (2021-2032)
- 4.5 South America Live Attenuated Herpes Zoster Vaccine Consumption Value (2021-2032)
- 4.6 Middle East & Africa Live Attenuated Herpes Zoster Vaccine Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Live Attenuated Herpes Zoster Vaccine Sales Quantity by Type (2021-2032)
- 5.2 Global Live Attenuated Herpes Zoster Vaccine Consumption Value by Type (2021-2032)
- 5.3 Global Live Attenuated Herpes Zoster Vaccine Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2021-2032)
- 6.2 Global Live Attenuated Herpes Zoster Vaccine Consumption Value by Application (2021-2032)
- 6.3 Global Live Attenuated Herpes Zoster Vaccine Average Price by Application (2021-2032)
7 North America
- 7.1 North America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Type (2021-2032)
- 7.2 North America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2021-2032)
- 7.3 North America Live Attenuated Herpes Zoster Vaccine Market Size by Country
- 7.3.1 North America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Country (2021-2032)
- 7.3.2 North America Live Attenuated Herpes Zoster Vaccine Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Live Attenuated Herpes Zoster Vaccine Sales Quantity by Type (2021-2032)
- 8.2 Europe Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2021-2032)
- 8.3 Europe Live Attenuated Herpes Zoster Vaccine Market Size by Country
- 8.3.1 Europe Live Attenuated Herpes Zoster Vaccine Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Live Attenuated Herpes Zoster Vaccine Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Live Attenuated Herpes Zoster Vaccine Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Live Attenuated Herpes Zoster Vaccine Market Size by Region
- 9.3.1 Asia-Pacific Live Attenuated Herpes Zoster Vaccine Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Live Attenuated Herpes Zoster Vaccine Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Type (2021-2032)
- 10.2 South America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2021-2032)
- 10.3 South America Live Attenuated Herpes Zoster Vaccine Market Size by Country
- 10.3.1 South America Live Attenuated Herpes Zoster Vaccine Sales Quantity by Country (2021-2032)
- 10.3.2 South America Live Attenuated Herpes Zoster Vaccine Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Live Attenuated Herpes Zoster Vaccine Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Live Attenuated Herpes Zoster Vaccine Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Live Attenuated Herpes Zoster Vaccine Market Size by Country
- 11.3.1 Middle East & Africa Live Attenuated Herpes Zoster Vaccine Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Live Attenuated Herpes Zoster Vaccine Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Live Attenuated Herpes Zoster Vaccine Market Drivers
- 12.2 Live Attenuated Herpes Zoster Vaccine Market Restraints
- 12.3 Live Attenuated Herpes Zoster Vaccine Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Live Attenuated Herpes Zoster Vaccine and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Live Attenuated Herpes Zoster Vaccine
- 13.3 Live Attenuated Herpes Zoster Vaccine Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Live Attenuated Herpes Zoster Vaccine Typical Distributors
- 14.3 Live Attenuated Herpes Zoster Vaccine Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
According to our (Global Info Research) latest study, the global Live Attenuated Herpes Zoster Vaccine market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Live Attenuated Herpes Zoster Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Live Attenuated Herpes Zoster Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Live Attenuated Herpes Zoster Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Live Attenuated Herpes Zoster Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Live Attenuated Herpes Zoster Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Live Attenuated Herpes Zoster Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Live Attenuated Herpes Zoster Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck & Co., SK Bioscience, GlaxoSmithKline (GSK), Beike Bio, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Live Attenuated Herpes Zoster Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
40-50 Years Old
50-60 Years Old
60-70 Years Old
>70 Years Old
Market segment by Application
Hospital
Clinic
Epidemic Prevention Center
Others
Major players covered
Merck & Co.
SK Bioscience
GlaxoSmithKline (GSK)
Beike Bio
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Live Attenuated Herpes Zoster Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Live Attenuated Herpes Zoster Vaccine, with price, sales quantity, revenue, and global market share of Live Attenuated Herpes Zoster Vaccine from 2021 to 2026.
Chapter 3, the Live Attenuated Herpes Zoster Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Live Attenuated Herpes Zoster Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Live Attenuated Herpes Zoster Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Live Attenuated Herpes Zoster Vaccine.
Chapter 14 and 15, to describe Live Attenuated Herpes Zoster Vaccine sales channel, distributors, customers, research findings and conclusion.